Baicalein inhibits HMGB1 release and MMP-2/-9 expression in lipopolysaccharide-induced cardiac hypertrophy

Am J Chin Med. 2014;42(4):785-97. doi: 10.1142/S0192415X14500505.

Abstract

Myocardial dysfunction, a common complication after sepsis, significantly contributes to the death of patients with septic shock. In the search for potentially effective drugs to decrease mortality from sepsis, we investigated the cardioprotective effects of baicalein, a flavonoid present in the root of Scutellaria baicalensis, on lipopolysaccharide (LPS)-induced pro-inflammatory cytokine production and matrix metalloproteinase-2 and -9 (MMP-2/-9) expression. We found that baicalein significantly attenuated LPS-induced cardiac hypertrophy and counteracted reactive oxygen species (ROS) generation in neonatal rat cardiomyocytes. In addition, pretreatment with baicalein inhibited LPS-induced early (e.g., tumor necrosis factor-α (TNF-α) and interleukin-6) and late (e.g., high mobility group box 1 (HMGB1) pro-inflammatory cytokine release, inducible nitric oxide synthase (iNOS) expression and NO production. Finally, baicalein also significantly down-regulated the expression of MMP-2/-9 and attenuated HMGB1 translocation from the nucleus to the cytoplasm. These results suggest that baicalein can protect cardiomyocytes from LPS-induced cardiac injury via the inhibition of ROS and inflammatory cytokine production. These cardioprotective effects are possibly mediated through the inhibition of the HMGB1 and MMP-2/-9 signaling pathways.

Keywords: Baicalein; Cardiac Hypertrophy; High Mobility Group Box 1; Lipopolysaccharide; Matrix Metalloproteinases; Reactive Oxygen Species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use*
  • Cardiomegaly / chemically induced
  • Cardiomegaly / drug therapy*
  • Cardiomegaly / genetics*
  • Cardiomegaly / pathology
  • Cells, Cultured
  • Down-Regulation / drug effects
  • Flavanones / pharmacology*
  • Flavanones / therapeutic use*
  • HMGB1 Protein / metabolism*
  • Lipopolysaccharides*
  • Matrix Metalloproteinase 2 / metabolism*
  • Matrix Metalloproteinase 9 / metabolism*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Nitric Oxide Synthase Type II / metabolism
  • Phytotherapy*
  • Protein Biosynthesis / drug effects
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Scutellaria baicalensis

Substances

  • Antioxidants
  • Flavanones
  • HMGB1 Protein
  • Hbp1 protein, rat
  • Lipopolysaccharides
  • Reactive Oxygen Species
  • baicalein
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9